Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Genpact's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Genpact's regulatory disclosures and financial reporting.
Company G filed a notice of proposed sale of common stock by insider Anil Nanduru. The filing lists up to 11,852 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services in New York.
The proposed sale consists of 8,000 Performance Shares dated January 10, 2025 and 3,852 shares of Restricted Stock dated January 10, 2026, in two blocks of 2,794 and 1,058 shares. The filing also reports that during the past three months, Nanduru sold 17,243 common shares on August 11, 2026 for approximately 585,568.83.
G filed a notice of proposed sale of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza, New York. The filing lists 17,243 common shares to be sold on the NYSE with a planned sale date of 08/11/2026. It also reports prior planned sales of 11,050 restricted stock shares dated 01/10/2026 and 6,193 performance shares dated 03/10/2026.
Genpact Limited reported higher Q2 2026 results with amounts presented in thousands of dollars. Net revenues were $1,343,438 versus $1,254,418 a year earlier, and net income was $145,737 versus $132,716, for diluted EPS of $0.86 versus $0.75. For the first half of 2026, net revenues reached $2,639,510 and net income $293,729, both above 2025 levels.
Growth came across all segments: Financial Services revenue was $349,890, Consumer and Healthcare $469,172, and High Tech and Manufacturing $524,376 in Q2 2026. Operating cash flow for the first half decreased to $48,908 from $217,801, influenced by a larger increase in accounts receivable and other working-capital items. Investing activities provided $299,769, including $350,000 from maturing short-term investments. Cash and cash equivalents were $517,387, with short-term investments of $350,000, total assets of $5,413,096, and equity of $2,604,797.
Long-term debt fell to $1,180,257 from $1,542,301 after repayment of the 1.750% 2021 Senior Notes. In the first half, Genpact repurchased 3,372,227 shares for $119,940 and paid dividends totaling $0.3750 per share, or $63,325. The company also paid the final $77,500 earn-out for its XponentL Data acquisition, bringing total consideration to $160,157.
Genpact Limited reported that it issued a press release on August 6, 2026 presenting its financial results for the three months ended June 30, 2026. The release is provided as an exhibit and treated as information furnished under the Exchange Act, rather than filed.
The company indicates that the press release and related conference call include non-GAAP financial measures, with reconciliations to the most directly comparable GAAP figures included in the press release. The press release is incorporated by reference only where specifically identified in future securities filings.
Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of Genpact Ltd common stock on an amended Schedule 13G. The group holds 10,420,948 shares, representing 6.14% of the outstanding class as of June 30, 2026. Vanguard reports sole voting power over 116,538 shares and sole dispositive power over all 10,420,948 shares, with no shared voting or dispositive power. The position includes securities held by Vanguard funds and managed accounts over which these entities exercise voting and/or dispositive authority. Vanguard notes that various clients and funds have rights to dividends and sale proceeds, but no single other person has an interest in more than 5% of the class.
FMR LLC filed an amendment to Schedule 13G/A reporting beneficial ownership of 10,405,025.34 shares of Genpact Ltd. (CUSIP G3922B107), representing 6.1% of the class as of 06/30/2026. The filing states sole dispositive power for 10,405,025.34 shares and sole voting power reported on the cover page. The filing is submitted on behalf of FMR LLC and references Abigail P. Johnson in the cover-page data; signatures are provided under a power of attorney dated 04/13/2026. Exhibit 99 and Exhibit 24 are referenced for subsidiary/authority details.
AQR Capital Management Holdings, LLC and AQR Capital Management, LLC reported beneficial ownership of 11,278,646 common shares of Genpact Ltd. That stake represents 6.64% of Genpact's outstanding common shares as of 03/31/2026. The filing shows shared voting power of 10,971,639 shares and shared dispositive power of 11,278,646 shares. The filing identifies AQR Capital Management, LLC as a wholly owned subsidiary of AQR Capital Management Holdings, LLC and is signed by an authorized signatory on behalf of both entities.
Genpact Limited reported higher results for the quarter ended March 31, 2026. Net revenues rose to $1,296,072 thousand from $1,214,926 thousand a year earlier, while net income increased to $147,992 thousand from $130,853 thousand. Diluted earnings per share improved to $0.86 from $0.73.
Operating cash flow turned negative at $(23,535) thousand versus positive $40,436 thousand in the prior-year quarter, reflecting higher working capital use. Cash and cash equivalents declined to $578,079 thousand from $853,836 thousand at year-end 2025, partly after paying a $77,500 thousand earn-out related to the XponentL Data acquisition. Total assets were $5,617,239 thousand and equity was $2,475,193 thousand as of March 31, 2026.
Genpact Limited reported solid first quarter 2026 results with net revenues of $1.296 billion, up 6.7% year-over-year. Advanced Technology Solutions revenue grew 24.3% to $345 million, reaching 27% of total net revenues, while Core Business Services rose 1.4% to $951 million.
Gross profit increased to $472 million with a margin of 36.4%, marking the 12th consecutive quarter of year-over-year gross margin expansion. Net income was $148 million, up 13.1%, and diluted EPS was $0.86, up 17.8%. Adjusted diluted EPS was $0.98, up 16.7%.
Operating cash flow was a use of $24 million compared to $40 million generated in the prior-year quarter, and the company repurchased about 1.8 million shares for roughly $70 million. For Q2 2026, Genpact guides net revenues of $1.324–$1.336 billion and adjusted diluted EPS of $0.96–$0.97. For full-year 2026, it expects net revenue growth of at least 7% and adjusted diluted EPS growth of more than 10%.
Genpact Ltd ownership filing reports that Vanguard Capital Management beneficially owned 8,674,784 shares of Genpact common stock, representing 5.10% of the class as of 03/31/2026. The filing discloses sole voting power for 1,216,854 shares and sole dispositive power for 8,674,784 shares. The filing notes these holdings reflect securities managed by Vanguard Capital Management and certain affiliated Vanguard business divisions.